Human health risk assessment of carbamazepine in surface waters of North America and Europe

Regulatory Toxicology and Pharmacology

Volumn 56, Issue 3, 2010, Pages 343-351

  Cunningham, Virginia L ^a   Perino, Christopher ^b   D'Aco, Vincent J ^c   Hartmann, Andreas ^b   Bechter, Rudolf ^b  

^a Sustainability Sciences LLC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Quantum Management Group   (United States)

Author keywords

Carbamazepine; GREAT ER; Human health; Pharmaceutical; PhATE; Risk assessment

Indexed keywords

10,11 DIHYDRO 10,11 DIHYDROXYCARBAMAZEPINE; CARBAMAZEPINE; CARBAMAZEPINE N GLUCURONIDE; DRINKING WATER; DRUG METABOLITE; SURFACE WATER; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTICLE; ATAXIA; BIOTRANSFORMATION; BLOOD TOXICITY; DIZZINESS; DROWSINESS; DRUG HYPERSENSITIVITY; ENVIRONMENTAL EXPOSURE; EPOXIDATION; EUROPE; FISH; FOOD INTAKE; GLUCURONIDATION; HEALTH HAZARD; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; MUTAGENICITY; NAUSEA; NORTH AMERICA; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; THROMBOCYTE COUNT; TRIGEMINUS NEURALGIA; UNSTEADINESS; URTICARIA; VOMITING; WATER SUPPLY;

ANTIMANIC AGENTS; CARBAMAZEPINE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; EUROPE; FRESH WATER; HUMANS; KINETICS; NORTH AMERICA; RISK ASSESSMENT; WATER POLLUTANTS, CHEMICAL; WATER SUPPLY;

APIS;

EID: 77249175245     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2009.10.006     Document Type: Article

References (72)

1. ACD. Advanced Chemistry Development, Version 9.0. ACD/Labs.
2. Ahrer W., et al. Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry. Journal of Chromatography A 910 (2001) 69-78
3. Anderson J.V., et al. Enzymic synthesis of two glucuronides of the hydroxyisoxazole GABA-agonist, THIP, and the in vivo glucuronidation of THIP in rats. Xenobiotica 19 (1989) 1399-1406
4. Anderson P.D., et al. Screening analysis of human pharmaceutical compounds in U.S. surface waters. Environmental Science & Technology 38 (2004) 838-849
5. Andreozzi R., et al. Carbamazepine in water: persistence in the environment, ozonation treatment and preliminary assessment on algal toxicity. Water Research 36 (2002) 2869-2877
6. Apotex Corporation, 2002. Carbamazepine Tablets USP. Package Insert with Prescribing Information.
7. Axelrod J., et al. Enzymatic synthesis of N-glucosyluronic acid conjugates. Journal of Biological Chemistry 232 (1961) 835-841
8. Bendz D., et al. Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Höje River in Sweden. Journal of Hazardous Materials 122 (2005) 195-204
9. Benotti M., and Brownawell B. Distributions of pharmaceuticals in an urban estuary during both dry- and wet-weather conditions. Environmental Science & Technology 41 (2007) 5795-5802
10. Bercu J.P., et al. Human health risk assessments for three neuropharmaceutical compounds in surface waters. Regulatory Toxicology and Pharmacology 50 (2008) 420-427
11. Christensen F.M. Pharmaceuticals in the environment - a human risk?. Regulatory Toxicology and Pharmacology 28 (1998) 212-221
12. Clara M., et al. Carbamazepine as a possible anthropogenic marker in the aquatic environment: investigations on the behaviour of Carbamazepine in wastewater treatment and during groundwater infiltration. Water Research 38 (2004) 947-954
13. Comoretto L., and Chiron S. Comparing pharmaceutical and pesticide loads into a small Mediterranean river. Science of the Total Environment 349 (2005) 201-210
14. Cunningham V.L., et al. Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. Regulatory Toxicology and Pharmacology 53 (2009) 39-45
15. Cunningham V.L., et al. Effects of human pharmaceuticals on aquatic life: next steps. Environmental Science & Technology 40 (2006) 3456-3462
16. Daylight, 2005. Daylight Version 4.9, Release Date 04/08/05. Daylight Chemical Information Systems, Inc.
17. Dickinson R.G., et al. Carbamazepine. In: Eadie M.J., and Vajda F.J.E. (Eds). Antiepileptic Drugs: Pharmacology and Therapeutics: Handbook of Experimental Pharmacology vol. 138 (1999), Springer-Verlag, Berlin 271-317
18. Doll T.E., and Frimmel F.H. Photocatalytic degradation of carbamazepine, clofibric acid and iomeprol with P25 and Hombikat UV100 in the presence of natural organic matter (NOM) and other organic water constituents. Water Research 39 (2005) 403-411
19. European Commission, 2003. Technical Guidance Document on Risk Assessment, Part II, European Communities, Table 16, p. 20. Available from: .
20. Faigle J.W., et al. The biotransformation of carbamazepine. In: Birkmayer W. (Ed). Epileptic Seizure-Behaviour-Pain (1976), University Park Press, London 127-140
21. Faigle J.W., and Feldmann K.F. Pharmacokinetic data of carbamazepine and its major metabolites in man. In: Birkmayer W. (Ed). Epileptic Seizure-Behaviour-Pain (1976), University Park Press, London 159-165
22. Faigle J.W., and Feldmann K.F. Carbamazepine biotransformation. In: Woodbury D.M., et al. (Ed). Antiepileptic Drugs (1982), Raven Press, Ltd., New York 483-495
23. Faigle J.W., and Feldmann K.F. Carbamazepine chemistry and biotransformation. In: Levy R.H., et al. (Ed). Antiepileptic Drugs (1995), Raven Press, Ltd., New York 499-513
24. Feijtel T.C.J., et al. Development of a Geography-referenced Regional Exposure Assessment Tool for European Rivers - GREAT-ER. Contribution to GREAT-ER # 1. Chemosphere 34 (1997) 2351-2373
25. Focazio M.J., et al. A national reconnaissance for pharmaceuticals and other organic wastewater contaminants in the United States - II. Untreated drinking water sources. Science of the Total Environment 402 (2008) 192-200
26. Fox K.K., et al. The use of measured boron concentration data from the GREAT-ER UK validation study (1996-1998) to generate predicted regional boron concentrations. The Science of the Total Environment 251 252 (2000) 305-316
27. Gagneux A.R. The chemistry of carbamazepine. In: Birkmayer W. (Ed). Epileptic Seizure-Behaviour-Pain (1976), Huber Publishers, Berne 58-65
28. Hao C., et al. Determination of pharmaceuticals in environmental waters by liquid chromatography/electrospray ionization/tandem mass spectrometry. Analytical and Bioanalytical Chemistry 384 (2006) 505-513
29. Heberer T. Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of current research data. Toxicology Letters 131 (2002) 5-17
30. Heberer T., and Feldmann D. Contribution of effluents from hospitals and private households to the total loads of diclofenac and carbamazepine in municipal sewage effluents - modeling versus measurements. Journal of Hazardous Materials 122 (2005) 211-218
31. Huber M.M., et al. Oxidation of pharmaceuticals during ozonation and advanced oxidation processes. Environmental Science & Technology 37 (2003) 1016-1024
32. Hummel D., et al. Simultaneous determination of psychoactive drugs and their metabolites in aqueous matrices by liquid chromatography mass spectrometry. Environmental Science & Technology 40 (2006) 7321-7328
33. IMS Health, Inc., 2005. IMS Midas Quantum Year End 2004.
34. Jones O.A.H., et al. Potential ecological and human health risks associated with the presence of pharmaceutically active compounds in the aquatic environment. Critical Reviews in Toxicology 34 (2004) 335-350
35. Joss A., et al. Removal of pharmaceuticals and fragrances in biological wastewater treatment. Water Research 39 (2005) 3139-3152
36. Kolpin D.W., et al. Pharmaceuticals, hormones, and other organic wastewater contaminant in U.S. streams, 1999-2000: a national reconnaissance. Environmental Science & Technology 36 (2002) 1202-1211
37. Lam M.W., et al. Aquatic persistence of eight pharmaceuticals in a microcosm study. Environmental Toxicology and Chemistry 23 (2004) 1431-1440
38. Loos R., et al. EU Wide Monitoring Survey of Polar Persistent Pollutants in European River Waters (2008), European Commission, Joint Research Centre, Institute for Environment and Sustainability EUR 23568 EN.
39. McDonald R.L. Carbamazepine mechanisms of action. In: Levy R.H., et al. (Ed). Antiepileptic Drugs (2002), Lippincoll Williams & Wilkins, Philadelphia 227-235
40. Meylan W.M., et al. Improved method for estimating bioconcentration/bioaccumulation factor from octanol/water partition coefficient. Environmental Toxicology and Chemistry 18 (1999) 664-672
41. Miao X.-S., et al. Carbamazepine and its metabolites in wastewater and in biosolids in a municipal wastewater treatment plant. Environmental Science & Technology 39 (2005) 7469-7475
42. Novartis, 1996. Tegretol-Xr (Carbamazepine Extended Release Tablets). NDA #020234. Available from: .
43. Novartis, 2007. Tegretol®-XR (Carbamazepine Extended-Release Tablets) 100 mg, 200 mg, 400 mg Prescribing Information, vol. 2007, p. 1. Available from: (accessed 12.03.07).
44. Novartis Pharmaceuticals Corporation, 2006. Tegretol® and Tegretol®-XR. Prescribing Information.
45. Paxéus N.A. Removal of selected non-steroidal anti-inflammatory drugs (NSAIDs), gemfibrozil, carbamazepine, b-blockers, trimethoprim and triclosan in conventional wastewater treatment plants in five EU countries and their discharge to the aquatic environment. Water Science and Technology 50 (2004) 253-260
46. Physicians' Desk Reference, 2004. 58th Ed. Thomson PDR, Montvale, NJ.
47. Rapaport R.A. Prediction of consumer product chemical concentrations as a function of publicly owned treatment works treatment type and river dilution. Environmental Toxicology and Chemistry 7 (1988) 107-115
48. Schulman L.J., et al. A human health risk assessment of pharmaceuticals in the aquatic environment. Human and Ecological Risk Assessment 8 (2002) 657-680
49. Schwab B.W., et al. Human pharmaceuticals in U.S. surface water: a human health risk assessment. Regulatory Toxicology and Pharmacology 42 (2005) 296-312
50. Shire, 2006. Carbatrol®. Prescribing Information.
51. Spina E. Carbamazepine chemistry, biotransformation, and pharmacokinetics. In: Levy R.H., et al. (Ed). Antiepileptic Drugs vol. 5 (2002), Lippincott Williams & Wilkins, Philadelphia 240
52. Stackelberg P.E., et al. Persistence of pharmaceutical compounds and other organic wastewater contaminants in a conventional drinking water treatment plant. Science of the Total Environment 329 (2004) 99-113
53. Stackelberg P.E., et al. Efficiency of conventional drinking-water-treatment processes in removal of pharmaceuticals and other organic compounds. Science of the Total Environment 377 (2007) 255-272
54. Sviranov D.A., and Pippenger C.E. Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication. Therapeutic Drug Monitoring 18 (1996) 660-665
55. Ternes T.A. Occurrence of drugs in German sewage treatment plants and rivers. Water Research 32 (1998) 3245-3260
56. Ternes T.A. Pharmaceuticals and metabolites as contaminants of the aquatic environment. In: Daughton C.G., and Jones-Lepp T.L. (Eds). Pharmaceuticals and Personal Care Products in the Environment: Scientific and Regulatory Issues (2001), American Chemical Society, Washington, DC 23-34
57. Ternes T.A., et al. Removal of pharmaceuticals during drinking water treatment. Environmental Science & Technology 36 (2002) 3855-3863
58. Ternes T.A., et al. Pharmaceuticals in groundwaters: analytical methods and results of a monitoring program in Baden-Wurttemberg, Germany. Journal Chromatography A 938 (2001) 199-210
59. Ternes T.A., et al. Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater?. Water Research 37 (2003) 1976-1982
60. Togola A., and Budzinski H. Multi-residue analysis of pharmaceutical compounds in aqueous samples. Journal of Chromatography A 1177 (2008) 150-158
61. U.S. EPA, 1992. Guidelines for Exposure Assessment. EPA/600/Z-92/001, p. 81.
62. U.S. EPA, 2000. Methodology for Deriving Ambient Water Quality Criteria for the Protection of Human Health. Office of Water, Office of Science and Technology. EPA 822 B 00 004, October 2000.
63. U.S. EPA, 2005. Exposure and Fate Assessment Screening Tool (E-FAST), Version 2.0, October 2005, pp. 3-29. Available from: .
64. U.S. FDA, 1999. Benefit vs. risk: how CDER approves new drugs. In: From Test Tube to Patient: Improving Health through Human Drugs. U.S. Food and Drug Administration Center for Drug Evaluation and Research Special Report, pp. 33-40.
65. United States Pharmacopeia, 2005. Carbamazepine. Material Safety Data Sheet.
66. Validus, 2007. Equetro™. Prescribing Information.
67. Versteeg D.J., et al. Environmental exposure modeling and monitoring of human pharmaceuticals in the environment. In: Williams R.T. (Ed). Science for Assessing the Impacts of Human Pharmaceuticals on Aquatic Ecosystems (2005), SETAC Press, Pensacola, FL 71-110
68. Webb S., et al. Indirect exposure to pharmaceuticals via drinking water. Toxicology Letters 142 (2003) 157-167
69. Wedlund P.L., et al. Steady-state determination of the contribution of lung metabolism to the total body clearance of drugs: application to carbamazepine. Journal of Pharmaceutical Sciences 72 (1983) 860-862
70. World Health Organization, 1999. International Programme for Chemical Safety. INCHEM. Carbamazepine.
71. Yu Z., et al. Optimizing gas chromatographic-mass spectrometric analysis of selected pharmaceuticals and endocrine-disrupting substances in water using factorial experimental design. Journal of Chromatography A 1148 (2007) 65-77
72. Zhang Z., et al. Analysis of emerging contaminants in sewage effluent and river water: comparison between spot and passive sampling. Analytica Chimica Acta 608 (2008) 37-44